Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases by Giuseppe Traversa et al.
RESEARCH Open Access
Italian program for independent research
on drugs: 10 year follow-up of funded
studies in the area of rare diseases
Giuseppe Traversa1*, Lucia Masiero2, Luciano Sagliocca3 and Francesco Trotta4
Abstract
Background: In 2005 the Italian Medicines Agency (AIFA) started a program on independent research on drugs,
with the aim to promote clinical research in areas of limited commercial interest. For 3 years (2005–2007) an area of
the program was reserved to studies in the field of rare diseases. There is a concern that public funding of research
may be wasted. We investigated the outcome of the program.
Methods: We conducted a cohort study on the projects that were funded by the AIFA in the area of rare diseases.
The outcomes were the proportion of published studies, time to publication, impact factor of the publishing
journals and relevance for clinical practice. We retrieved published articles through a literature search in peer
reviewed biomedical journals indexed by Pubmed. We used the Kaplan–Meier method to estimate the cumulative
probability of publication by time from project starting to publication.
Results: During the period 2005–2007, 62 projects were funded in the area of rare diseases. Most of the studies
(n 39; 63 %) had a randomized design and in 22 (35 %) the control group received an active treatment. For
39 studies (63 %) we retrieved a publication in a peer reviewed journal. The median time to publication was
74 months and, at the maximum period of follow up (109 months), the cumulative probability of publication
reached 77 %. The median impact factor was 5.4 (range 1.4–52.4). Considering the clinical relevance, more than
30 % of the published articles presented conclusive findings; an additional 10 % of the studies reached potential
breakthrough findings.
Conclusions: Even though it takes time to set up and conduct a funding program for independent research on
drugs, the results are highly rewarding. Independent funding is crucial in supporting studies aimed at answering
questions that are relevant for clinical practice despite the lack of sufficient commercial interest.
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Background
In a world of limited resources, research investments need
to compete with alternative purposes. To oppose the
suggestion of wasting public funding, [1, 2] researchers
are required to demonstrate that they are acting in the
best interest of the society: focusing on relevant issues,
collaborating and sharing information to exploit as far as
reasonable the acquired data [3, 4], and publishing all
the available findings [5]. Documenting how funding
programs are managed and which results are obtained
should also be considered a responsibility of the re-
searchers’ community.
In 2005 the Italian Medicines Agency (AIFA) started a
program on independent research on drugs, with the
aim to promote clinical research in areas of limited com-
mercial interest [6, 7]. Finance for this program comes
through an innovative policy: all international and na-
tional pharmaceutical companies operating in Italy are
required to contribute 5 % of their yearly expenditure
for promotional initiatives to a national fund. For 3 years
(2005–2007) an area of the program was reserved to
studies in the field of rare diseases. The aim was to fund
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clinical studies to acquire additional information on the
benefit-risk profile of orphan drugs (either approved by
the European Medicines Agency, EMA, or holding an
“orphan drug designation”), and of drugs that were used
off-label in the treatment of rare diseases. Overall, 64
projects were approved in this area, for a total of 13.7
million euro [6, 7].
The call in the area of rare diseases was subsequently
discontinued and the entire program, after three succes-
sive calls (in 2008, 2010 and 2012), is currently on hold
[8]; the call launched in 2012 was finalized in March
2016. Various reasons may explain the suspension of the
program as well as the exclusion of the rare diseases
area. Among the others, some skepticism about the role
and the quality of independent research was present.
We deemed of interest for the community of re-
searchers and clinicians to document the results that
can be achieved by funding independent research, also
considering that relatively few examples are available.
The objective of the present paper is to assess the out-
come of the projects that were funded by AIFA in the field
of rare diseases in terms of study completion, publications
and potential implications for clinical practice.
Methods
Study design and setting
We conducted a retrospective cohort study based on all
projects that were approved for funding between 2005
and 2007 in the area of rare diseases in the AIFA pro-
gram for independent research on drugs. Details about
the characteristics of the program have been presented
elsewhere [6].
Each project was characterized in terms of: principal
investigator; year of the call; year of the contract; study
design (experimental vs observational); presence/absence
of a control group; presence/absence of randomization;
comparator for the primary outcome (placebo vs active
treatment); number of patients included; clinical area.
We adopted as starting point of the project the date in
which the contract between AIFA and the institution of
the principal investigator was signed. The list of project
titles and principal investigators was published previ-
ously [6]; the starting date was publicly available through
the AIFA website; further characteristics of the funded
studies (e.g., study design and planned sample size) were
obtained from two abstract books in which the initial
organization of the studies was presented in two follow-
up meetings held in 2008 and 2009 [9, 10].
Ascertainment of the publications
We carried out a literature search in peer reviewed bio-
medical journals indexed by Pubmed using the name of
the principal investigator together with keywords ex-
tracted from the project title. Two authors (FT, GT)
carried out the selection of the publications matching
project and publication titles. The full papers were re-
trieved and searched for an explicit reference to the
funding of the research project by AIFA. In a few cases,
no mention of the funding source was present. In these
instances, a publication was accepted when the following
three criteria were all met: the principal investigator of
the research project was one of the authors; project and
paper titles were matching; and the content of the paper
was the same already presented in the abstract books.
The publication status was ascertained after the starting
point of the project up to 30 November 2015. In one
case, we also accepted the personal communication by
one investigator of a funded project indicating that a
paper presenting the final results of the study had just
been submitted for publication.
When no publication was retrieved, two additional ex-
ploring activities were carried out. First, the project title
was searched in Google to verify if any publication was
mentioned (other than those included in the abstract book
previously cited). Second, we searched the archive of Clin-
icalTrials.Gov (CTG) and, when available, the website of
the project to verify if any information was provided about
the termination (prematurely or not) of the study, or the
possibility that the study was, for different reasons, to be
completed. We accepted as “ongoing” a study with an
updated profile mentioning that the completion was ex-
pected not before the beginning of 2016.
Relevance of the publications
For each article, the impact factor (IF) of the publishing
journal was obtained consulting the Journal Citation Re-
ports [11]. All IFs refer to the 5 year average 2009–2014.
The full text of each paper was analyzed to assess the
potential relevance of the findings in terms of type of
outcome (clinical vs surrogate) and implications for clin-
ical practice. As for the implications, the published arti-
cles were categorized according to the conclusions
stated by the authors as: 1) “potentially breakthrough”,
when the study findings might radically modify the clinical
prognosis of a disease or, in areas with previous uncertain-
ties, the findings demonstrated that one of the compared
options was drastically better than the other; 2) “conclu-
sive-positive” (beneficial) results, when the study results
presented in the article confirmed an option that was
previously considered as part of the armamentarium
for the treatment of a disease; 3) “conclusive-negative”
(unfavorable) results, when the study results presented
in the article disproved an option that was previously
considered as part of the armamentarium for the
treatment of a disease; 4) “potentially beneficial and
proof of concept”, when the study results were pre-
sented in the article as encouraging and deserving further
investigation.
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Statistical analysis
We described the main characteristics of the funded pro-
jects and of the published studies in terms of: prevalence
of the condition; study design (presence of control group;
presence of randomization); clinical area (oncology; con-
genital/genetic diseases; immune system disorders; others);
age of the study population; planned and actual enrolment.
Categorical variables (e.g., type of control group) were
reported as frequencies and percentages, and continuous
variables (e.g., impact factor) as median and interquartile
ranges (IQR). We used the Kaplan–Meier method to es-
timate the cumulative probability of publication by time
from project starting to publication, with sub-analyses by
elements of the study design (e.g., randomization, sample
size, outcomes); the observation was censored on 30
November 2015. Log-rank test was performed to compare
cumulative probability distributions. Logistic regression
was used to estimate the association (Odds Ratio, OR)
between study characteristics and the probability of pub-
lishing articles with greater relevance for clinical practice.
The statistical analysis was performed using STATA
software (version 12.1; StataCorp LP, College Station,
TX, USA). P < 0.05 (2-sided) was set as level of
significance.
Results
Characteristics of funded and published studies
Two of the 64 projects approved for funding during the
period 2005–2007 were not eligible for the analysis since
the initial contract was never signed, leaving a sample
of 62 studies (Fig. 1). For 63 % of the projects (39/
62) at least one publication on a peer-reviewed jour-
nal was retrieved (Additional file 1: Table S1), whereas
the remaining ones (23/62) were unpublished up to
November 2015.
The main characteristics of the published and unpub-
lished projects are reported in Table 1. Most of the stud-
ies were conducted in the field of oncology/hematology
(19), genetic diseases (17) and immunology (7), which
represent the three main areas of interest for rare dis-
eases. Two thirds of the conditions can be classified as
very rare, with a prevalence lower than 1/100,000 inhabi-
tants, and 29% refer to ultra-rare diseases affecting less
than one in a million people.
With regard to study design, 39 projects (63 %) were
randomized clinical trials (RCT): in 22 (35.5 %) the com-
parison included an active treatment, whereas the control
group was placebo or no treatment in 17 cases (27.4 %).
The median sample size of subjects enrolled in the studies
was 60 patients (IQR: 30–124). The patients’ populations
covered all age groups, with 18 of the 62 studies (29 %)
specifically devoted to the pediatric population.
No statistically significant difference was observed be-
tween published and unpublished studies with regard to
clinical area, prevalence of the disease, type of control
group, sample size, and special population involved. We
found a higher proportion of RCTs still unpublished
even though the difference did not reach statistical sig-
nificance (p = 0.055).
Time to publication
The median time from signing the contract to publication
of the study results was 74 months (IQR 49–84). The
cumulative probability of publication reached 77.2 % at
9 years of follow-up (Fig. 2).
The year of the call (Fig. 3a), the clinical area (Fig. 3b),
the prevalence of the disease (Fig. 3c) and the sample
size (Fig. 3d) did not influence the probability of publica-
tion. Given the differential length of follow-up, 80 %
(16/20) of the studies funded in 2005 vs 42 % (8/19) of
Fig. 1 Flow chart of the studies approved for funding in the area of rare diseases included in the analysis
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those funded in 2007 were published by November
2015. Although the cumulative probability of publication
over the 9 year period did not differ between study
designs, the presence of a randomized allocation of sub-
jects was associated with a longer median time to publi-
cation (Fig. 3e).
Restricting the analysis to published articles, we ob-
served that the robustness of the outcome (clinical vs
surrogate endpoints) and the IF of the journal were not
predictive factors of the time to publication (Additional
file 2: Figure S1 and Additional file 3: Figure S2). Only
the presence of a control group receiving an active treat-
ment was associated with a slightly longer time to publi-
cation (p = 0.047) (Additional file 4: Figure S3). We also
found a high consistency between the planned sample
size (as reported at the beginning of the study in the
abstract books) and the final number of subjects
reported in the published article (median difference 5
subjects; Additional file 5: Figure S4).
Relevance of publications and implication of findings for
clinical practice
Overall, the 39 published articles totaled 401 points of
IF (mean: 10.4; median: 5.4, IQR: 3.6-8.7).
Four articles (10 % of the published studies) had find-
ings that might represent a potential breakthrough in
clinical practice (Table 2). Twelve articles presented
convincing findings as either conclusive-positive (6/39;
15 %) or conclusive-negative (6/39; 15 %); the remaining
articles (23; 59 %) provided the proof of concept regard-
ing new treatment hypotheses and consequently re-
quired to be confirmed in further robust clinical studies
Table 1 Characteristics of the published and unpublished studies included in the analysis (n = 62)
Published Unpublished p(chi-square) Total
N % N % N %
Studies funded and started 39 62.9 23 37.1 62 100.0
Clinical area 0.604
Oncology/hematology 11 28.2 8 34.8 19 30.6
Congenital and genetic disorders 13 33.3 4 17.4 17 27.4
Immune system disorders 4 10.3 3 13.0 7 11.3
Other 11 28.2 8 34.8 19 30.6
Prevalence of rare disease 0.381
> 1/10,000 14 35.9 7 30.4 21 33.9
1–9/100,000 12 30.8 11 47.8 23 37.1
1–9/1,000,000 13 33.3 5 21.8 18 29.0
Study characteristics
Design 0.055
Randomized clinical trials (RCT) 21 53.8 18 78.3 39 62.9
Uncontrolled clinical trials (CT) 18 46.2 5 21.7 23 37.1
Type of control group (n = 39) 21 100.0 18 100.0 0.584 39 100.0
Active control 11 52.4 11 61.1 22 56.4
Placebo control/no treatment 10 47.6 7 38.9 17 43.6
Planned sample size (tertiles) 0.901
< =46 patients 13 33.3 8 34.8 21 33.9
47-100 patients 14 35.9 7 30.4 21 33.9
> 100 patients 12 30.8 8 34.8 20 32.3
Mean 98 107 101
Median 60 80 60
Q1-Q3 30–120 29–177 30–124
Special populations 0.307
Only pediatrics 12 30.8 6 26.1 18 29.0
Also pediatrics 4 10.3 0 0.0 4 6.5
Only adults 15 38.5 9 39.1 24 38.7
Adults and elderly 8 20.5 8 34.8 16 25.8
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(examples of studies in these categories are presented in
the Additional file 6: Table S2).
We also attempted to investigate if specific variables
(IF, sample size, robustness of outcome, randomization,
and treatment in the control group) were associated to
reaching conclusive findings (with immediate application
in clinical practice) in comparison to the “proof of con-
cept” studies. Although the sample of the published arti-
cles was small, resulting in wide confidence intervals, we
observed that a randomized design, robust endpoints
and high IF were associated with more clinically relevant
studies (Additional file 7: Table S3).
At least in one case the study results were explicitly
translated into a regulatory decision. On the basis of the
study findings, which was aimed at evaluating the effi-
cacy of low-dose rituximab in patients with refractory
HCV-associated mixed cryoglobulinemia, AIFA decided
that the tested posology could be provided by the NHS
to all patients with the condition under study [12].
Discussion
Assessing the outcomes of a funding program on inde-
pendent research on drugs requires answering three
main questions: 1) were the studies concluded and their
findings published? 2) were the results potentially relevant
for clinical practice and regulatory decisions? and 3) given
the overall outcomes, is it possible to substantiate the
specific role of independent research (or, essentially, would
any investment in research attain similar results)? Our
study suggests that a positive answer can be given to all
these issues.
Likelihood of concluding the studies and publishing the
results
During a median observation of 74 months almost two
thirds of the funded projects had an article published in
an indexed journal. The cumulative probability of publi-
cation reached 77.2 % at the maximum observation time
(9 years). Our publication rate is in the upper range of
what has been documented in analogous surveys.
Kasenda and coll., carried out a retrospective cohort on
RCTs that were approved by 6 research ethics commit-
tees in Switzerland, Germany and Canada between 2000
and 2003 [13]. Out of 894 RCTs involving patients, 530
(59.3 %) had a full publication within a median follow-
up of 11.6 years. Moreover, 4.9 % of the trials approved
by the ethics committees never started.
A systematic review carried out by the Cochrane
collaboration found that only 52.6 % of the study find-
ings that were presented as abstracts at scientific meet-
ings were published in a full article within the 9 years
following the abstract presentation [14]. The probability
of publication in full was slightly higher for randomized
trials (63.1 %).
Other studies focused on the publication rate of the
projects that were recorded in ClinicalTrials.gov. In a
cross-sectional analysis concerning 10 % of trials that
had been registered in CTG after December 1999 and
updated as being completed by June 2007, less than half
(311/677, 46 %) were published [15]. In a subsequent
analysis, Ross and coll. reviewed the pattern of publica-
tion of clinical trials that were funded by the National
Institutes of Health and registered in CTG [16]. Focus-
ing the analysis on clinical trials that were updated in
CTG as having been completed by December 2008,
68 % (249/635) were published in a peer reviewed bio-
medical journal whereas 32 % remained unpublished
after a median follow-up of 51 months from trial com-
pletion. Both surveys refer to registered trials that were
updated as being completed, and thus the denominator
does not take into account the studies that were re-
corded in CTG but did not update their profile mainly
because of early termination. A greater publication rate
observed in the AIFA program might be explained by a
specific point in the contract, according to which the re-
searchers were committed to disseminate research find-
ings through the publication on peer reviewed journals.
In early 2016, an analysis on rare disease trials regis-
tered in CTG showed that less than half of the studies
(47 %) had results published in scientific journals within
3 years after the conclusion [17]; moreover, only 35 % of
the studies had the findings reported at the CTG web-
site, despite the requirements of the US Food and Drug
Administration to posting results within 1 year after trial
completion.
Relevance of publications and implications for clinical
practice and regulatory decisions
Focusing on the impact factor of the published articles is
are producible approach to assess the relevance of the
Fig. 2 Kaplan-Meier curve of cumulative probability of publication
by time (months) since funding agreement and 95 % confidence
intervals in the analyzed cohort of studies
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study findings. Most of the studies funded by AIFA were
published in renowned medical journals, with a median
IF of 5.4 (and a mean of 10.4 per article). Of note, only
6.6 % (573 out of 8659) of the journals included in the
Journal Citation Reports have a 5 year IF higher than
5.38. Moreover, we made a comparison specifically
Fig. 3 Kaplan–Meier Plot of cumulative probability of publication by time (months) since funding agreement in the analyzed cohort by study
characteristics: Year, p = 0.8184 (Panel a); Clinical area, p = 0.9112 (Panel b); Disease prevalence, p = 0.3759 (Panel c); Planned sample size, p = 0.3989
(Panel d); Study design, i.e. CT vs RCT, p = 0.0531 (Panel e)
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referred to the Italian context. In 2014, the researchers
working in the Italian National Institute of Health (Isti-
tuto Superiore di Sanità), the largest research institution
of the Italian NHS, published 776 articles in indexed
journals, with an average IF of 3.87 [18].
When trying to classify the study outcome in terms of
relevance for clinical practice, the thought immediately
goes to findings that may radically change the prognosis
of a disease or condition, to potentially breakthrough
therapies, according to the terminology of the Food and
Drugs Administration (FDA). Even though at least four
studies reported findings that might be included in this
category, an important contribution to clinical practice
is also provided by confirmative studies, as well as by
studies that verified the lack of efficacy of available
treatments.
Confirmative studies are especially needed for orphan
drugs because the available evidence is often incomplete
when these drugs are approved by regulatory agencies.
An even lower level of evidence is inevitably accepted
when drugs that are marketed for non-rare diseases are
suggested, as off-label indications, for rare conditions. It
should be considered unethical that, given the lack of
sufficient funding of research, treatments that are not
adequately tested in clinical studies continue to be sug-
gested. In this regard, while studies confirming the bene-
ficial effect of an off-label drug provide a new option for
the treatment of rare diseases, negative findings are also
highly informative in order to prevent useless treatments
and to avoid wasting resources.
Independent research programs may also be relevant in
terms of economic implications. The findings of the study
conducted by Peyvandi et al. on patients with Hemophilia
A indicate that the plasma-derived factor VIII has a better
benefit-risk profile than the far more expensive recombin-
ant ones [19]. In Italy, in 2015, the overall expenditure for
factor VIII was estimated at 200 million euro [20], and
80 % of the use is accounted for by recombinant formula-
tions [21]. Considering that plasma derived factor VIII
costs at least 30 % less than the recombinant one, the sav-
ings that can be achieved by the Italian National Health
Service, in a single year, would be larger than the entire
amount of the money allocated for the funding of the 62
studies in the area of rare diseases.
The specificity of independent research funding programs
The role of independent research is to focus on relevant
research questions in areas of limited commercial inter-
est. Rare diseases represent a paradigmatic example. The
likelihood of economic return decreases with the de-
creasing prevalence of the condition. Moreover, the
commercial interest is not only inevitably lacking when
studying off-patent drugs, but also limited when asses-
sing the role of a patented drug in off-label indications.
If the drug is already recommended, no increasing sales
may derive when the study results support the efficacy,
whereas negative findings would damage the marketing.
Finally, and in common with non-rare diseases, carrying
out comparative RCTs with an active treatment would
normally be regarded a riskier activity.
It is thus not surprising that rare diseases are often
considered a difficult area to conduct clinical studies. An
analysis based on the CTG database compared interven-
tional clinical trials in rare vs. non-rare diseases by
reviewing the main characteristics of 24,088 trials regis-
tered between January 2006 and September 2012 [22].
Rare disease trials (2,759; 11.5 % of the total) enrolled
fewer participants (median 29 vs 62) and were less likely
Table 2 Studies with potentially breakthrough findings
• The project coordinated by Tiziano Barbui was aimed at comparing,
in patients with polycythemia vera, two therapeutic strategies (based
on pharmacological and non-pharmacological interventions) in the
prevention of thrombotic events. In a RCT that included 365 patients,
the strategy aimed at maintaining the hematocrit target at less than
45 % (aggressive strategy) was associated with a significantly lower rate
of cardiovascular death and major thrombosis in comparison with the
group of patients with a hematocrit target of 45 to 50 % (hazard ratio
in the high-hematocrit group, 3.91; 95 % CI, 1.45 to 10.53) [25].
• In patients with acute myeloid leukaemia, the standard myeloablative
conditioning treatment of busulphan plus cyclophosphamide is
associated with a substantial non-relapse mortality. An alternative
combination of busulfan and fludarabine has been proposed to reduce
the incidence of these events. In a multicenter study, Rambaldi and
coll. randomized 252 patients (aged 40-65 years) with acute myeloid
leukaemia to compare the two regimens [26]. The 1-year non-relapse
mortality was 17.2 % in the busulfan plus cyclophosphamide group
and 7.9 % in the busulfan plus fludarabine group (Gray's test p=0.026).
No difference was observed in terms of serious adverse events. The
Authors concluded that, in older patients with acute myeloid leukemia,
the busulfan plus fludarabine regimen “should be regarded as standard
of care during the planning of allogeneic transplants”.
• This example refers to a multicenter, randomized, study that
compared plasma-derived (PD) with recombinant (R) factor VIII with
regard to the risk of developing autoantibodies that neutralize the
coagulant activity of factor VIII [19]. Between 2010 and 2014, 251
previously untreated patients with severe hemophilia A were randomized
to the recombinant or the plasma-derived products. The cumulative
incidence of developing factor VIII inhibitors was higher in the
recombinant than in the plasma-derived group (hazard ratio 1.87; 95 % CI
1.18-2.97). These findings are of special importance also for low- and
middle-income countries when considering that the plasma-derived
factor VIII is far less expensive than the recombinant product.
• In this study, AIFA co-founded a project (already supported by
Telethon charity) with the aim to extend the number of patients
receiving a gene therapy for the treatment of an extremely rare and
severe congenital immunodeficiency due to adenosine deaminase
deficiency (ADA) [27]. Aiuti and coll. were able to demonstrate that the
treatment could radically modify the prognosis of these patients. After
4 years of follow up, all ten patients were alive and for 8 of them the
enzyme-replacement therapy was not required. The findings of the
study originated an agreement between Telethon and a pharmaceutical
company for the developing and marketing of an “industrialized”
product and the recognition of an orphan drug designation by EMA
http://www.pharmafile.com/news/396244/gsk-files-ultra-rare-disease-
application-ema.
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randomized (35.5 % vs 71.6 %). By comparison, the 62
studies that were funded by AIFA were more similar to
the non-rare disease group of trials in terms of partici-
pants (median of 60 patients) and proportion of ran-
domized studies (62.9 %).
These data testify that robust study designs can be
adopted in the area of rare diseases. They also suggest
that independent research is more likely to contribute
when the assessment of the end points requires long-
term follow-up and, predictably, longer time intervals
before conclusion. For instance, in an RCT aimed at
assessing the efficacy of adjuvant mitotane in prolonging
recurrence-free survival in patients with adrenocortical
carcinoma at low-intermediate risk of recurrence after
complete resection, the website of the project indicated
that the conclusion was expected by the end of 2015
(https://clinicaltrials.gov/ct2/show/NCT00777244). This
project was funded to test in a randomized study the
promising results of an observational study [23]. By de-
sign, the duration of the study had an expected minimum
duration of 6 years: 4 years for the enrollment period and
2 years of follow-up. Taking into account the enormous
amount of work that is devoted to conduct long-term
studies, it is likely that relevant publications will follow.
Limitations of the study
We cannot exclude that, despite the extensive search
that was carried out, we may have missed some of the
study publications, which would underestimate the suc-
cess rate. This is probably the case since after the end of
the study follow up (November 2015) the results of a
trial funded in 2006 in the setting of juvenile dermato-
myositis (demonstrating that prednisone and either
ciclosporin or methotrexate was more effective than
prednisone alone) were published in the Lancet [24].
Moreover, even considering a long-term follow-up (with
a maximum duration of 109 months for the 2005 call)
there is an underrepresentation of the publications rele-
vant to the 2007 (and partially 2006) projects. However,
the time to publication is similar for the 3 years and we
do not expect any change in the final publication rate.
As for the studies that were terminated before comple-
tion, no public information was available concerning the
reasons for the interruption. In any case, stopping a
study did not entail wasting public resources. By con-
tract, funding was transferred to the researcher’s institu-
tion only after having verified that specific milestones
were reached. In addition, in case of interruption, the re-
searcher’s institution was required to refund the resources
that were not already allocated.
Conclusions
The AIFA program ongoing between 2005 and 2007 in
Italy in the area of rare diseases can be considered a
success in terms of concluded studies, with a cumulative
probability of publication that reached almost 80 %. Our
data suggest that adequately powered randomized trials
can represent the gold standard also for rare diseases.
There are also important implications for clinical practice,
as can be expected by projects characterized by clinical
endpoints and extensive follow-up. It is unlikely that many
of these studies may have been conducted in a for profit
perspective, given the absence of commercial interest.
It is unfortunate that the Italian program for inde-
pendent research on drugs in the area of rare diseases
was only active for 3 years [8]. It is possible that the ab-
sence of short term results may have triggered a short-
sighted decision. We documented that, even though it
takes time to set up and conduct a funding program for
independent research, the overall results are highly re-
warding. Independent funding is crucial in supporting
studies aimed at answering questions that are relevant
for clinical practice despite the lack of sufficient com-
mercial interest.
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